| Not Yet Recruiting | A Clinical Trial Evaluating the Efficacy and Safety of Sanhuang Jingshiming Pills in the Treatment of nAMD NCT07269769 | Tasly Pharmaceutical Group Co., Ltd | Phase 3 |
| Not Yet Recruiting | Retinal Clinical Assessment With AI-derived Quantitative Information NCT07291960 | Beijing Tongren Hospital | — |
| Active Not Recruiting | A Real-World Study of Interventional Clinical Outcomes in Patients With Open Angle Glaucoma and Other Chronic NCT07216677 | Interstat LLC | — |
| Recruiting | Detection and Management of Sinusitis in a Single-center Prospective Cohort of Patients With Exudative AMD (SI NCT05547633 | Fondation Ophtalmologique Adolphe de Rothschild | — |
| Recruiting | Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-r NCT04796545 | VisionCare, Inc. | N/A |
| Recruiting | Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD NCT05407636 | AbbVie | Phase 3 |
| Enrolling By Invitation | Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD NCT05210803 | AbbVie | — |
| Completed | the Blood-Aqeous Barrier During Anti-Angiogenic Therapy in Exudative Age-Related Macular Degeneration NCT07375901 | The Filatov Institute of Eye Diseases and Tissue Therapy | N/A |
| Recruiting | Project AMD: Comprehensive Characterisation of Age-Related Macular Degeneration and Its Progression NCT04739319 | Center for Eye Research Australia | — |
| Withdrawn | Image Biomarkers for Progression of AMD NCT04537143 | Doheny Image Reading Center | — |
| Recruiting | Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One NCT04704921 | AbbVie | Phase 2 / Phase 3 |
| Unknown | Study to Evaluate the Response to Supplementation With Postbiotics in Patients With Macular Degeneration. NCT05056025 | Institut de la Macula y la Retina | N/A |
| Unknown | Evaluate the Improving Effects of Visucomplex Plus on Quality of Life in Patients With AMD NCT04177069 | VISUfarma SpA | — |
| Completed | Retinal Imaging Using NOTAL-OCT V3.0 NCT04078672 | Notal Vision Ltd. | N/A |
| Unknown | Quality-Assured Follow-up of Quiescent Neovascular Age -Related maculaR dEgeneration by Non-medical Practition NCT03893474 | Moorfields Eye Hospital NHS Foundation Trust | N/A |
| Completed | Phase 2/3 Study of ALK-001 in Geographic Atrophy NCT03845582 | Alkeus Pharmaceuticals, Inc. | Phase 2 / Phase 3 |
| Completed | Dual Wavelength OCT NCT03843840 | Moorfields Eye Hospital NHS Foundation Trust | — |
| Completed | Retinal Imaging Using NOTAL-OCT V2.5 NCT03600519 | Notal Vision Ltd. | — |
| Unknown | TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects NCT03675880 | Lee's Pharmaceutical Limited | Phase 1 |
| Completed | Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Re NCT03372746 | National Eye Institute (NEI) | — |
| Completed | Age-Related Eye Disease Study 2 (AREDS2) 10-year Follow-On NCT03367767 | National Eye Institute (NEI) | — |
| Completed | Vitamin A Palmitate Supplementation in People With Age-Related Macular Degeneration (and Without Reticular Pse NCT03478865 | National Eye Institute (NEI) | EARLY_Phase 1 |
| Completed | CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea (COCTAEyl) NCT03803631 | Centre Hospitalier Intercommunal Creteil | — |
| Unknown | The Effects of Regular Eye-training With a Mobile Device on Adult Patients With AMD NCT03461393 | University of Applied Sciences Upper Austria | — |
| Completed | Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP) NCT03322930 | Retina Foundation of the Southwest | — |
| Completed | Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age Related Macul NCT03324542 | Changhua Christian Hospital | — |
| Unknown | Treatment of Age-related Macular Degeneration by Fetal Retinal Pigment Epithelial Cells Transplantation NCT02868424 | The First Affiliated Hospital with Nanjing Medical University | EARLY_Phase 1 |
| Terminated | Resveratrol for Exudative Age-Related Macular Degeneration NCT02625376 | Poitiers University Hospital | N/A |
| Terminated | X-82 to Treat Age-related Macular Degeneration NCT02348359 | Tyrogenex | Phase 2 |
| Completed | Evaluating the Relationship Between Function and Structure in ARCHER II-like Population Using Data From a Natu NCT07424235 | IRCCS Ospedale San Raffaele | — |
| Terminated | Study of Retinal Findings in People With Signs and Symptoms of Alzheimer s Disease Enrolled in 09-M-0198 NCT02226835 | National Eye Institute (NEI) | — |
| Completed | Study of the Effects of Supplements on Eye Disease in Participants From the Age-Related Eye Disease Study NCT01915238 | National Eye Institute (NEI) | — |
| Completed | AMD Phenotype and Genotype Study NCT01778491 | National Eye Institute (NEI) | — |
| Completed | Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD) NCT01632527 | StemCells, Inc. | Phase 1 / Phase 2 |
| Recruiting | Cell Collection to Study Eye Diseases NCT01432847 | National Eye Institute (NEI) | — |
| Withdrawn | Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients NCT01339949 | Oraya Therapeutics, Inc. | N/A |
| Enrolling By Invitation | Post-Approval Study of the Implantable Miniature Telescope NCT01757132 | VisionCare, Inc. | N/A |
| Completed | INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD NCT01016873 | Oraya Therapeutics, Inc. | Phase 2 |
| Completed | Study the Signs of Ocular Degeneration in a Population Cohort (Dijon 3C Montrachet Cohort) NCT01766596 | Centre Hospitalier Universitaire Dijon | N/A |
| Completed | Low Vision Study Comparing EV Training vs. CCTV for AMD Rehabilitation NCT00971464 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Phase 2 |
| Withdrawn | Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneratio NCT00726466 | Vitreous -Retina- Macula Consultants of New York | Phase 1 |
| Terminated | Anecortave Acetate Risk Reduction Trial (AART) NCT00332657 | Alcon Research | Phase 3 |
| Completed | OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration NCT00306488 | National Institutes of Health Clinical Center (CC) | Phase 2 |
| Terminated | Anecortave Acetate Risk-Reduction Trial (AART) NCT00333216 | Alcon Research | Phase 3 |
| Completed | Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration NCT01570790 | Johns Hopkins University | Phase 1 / Phase 2 |
| Completed | Anecortave Acetate Versus Placebo in AMD Patients Following PDT NCT00346866 | Alcon Research | Phase 2 |
| Completed | A Phase II Study of Anecortave Acetate for the Treatment of Exudative Age-Related Macular Degeneration NCT00346957 | Alcon Research | Phase 2 |